Elon Musk stated that the brain is a biological computer, similar to silicon-based computers, with significant differences in processing capabilities and specialized skills among individuals. He believes that the potential capabilities of any brain can be inferred with high precision using MRI. He wrote that Neuralink must deeply understand the brain to effectively interface, leaving no room for empty talk.

The company has implanted a coin-sized N1 device in the skulls of paralyzed patients, using 1,024 electrodes to read the motor cortex's action potentials, which are wirelessly transmitted after on-chip compression and converted into a cursor or clicks by a model. The first implant recipient, Noland Arbaugh, uses it to browse the internet and play chess. Pre-surgery functional MRI located the hand and arm movement areas, which is part of the surgical planning, not a score for intelligence based on a structural image.

Musk has compared the brain to a computer for many years. Interface companies seek decodable discharge patterns and implantation coordinates that avoid blood vessels; "processing capacity can be measured with high precision by MRI" is another claim, but the article does not provide methods, errors, or peer-reviewed datasets. Cognitive neuroscience does show correlations between brain volume, connectomics, and certain test scores, but correlation does not equal high-precision predictions of individual capabilities, nor can it solely determine social stratification.

Neuralink's publicly stated goals include increasing human-machine bandwidth and long-term discussions about communication between humans and models, and between humans, with less language compression. The bandwidth narrative serves the expansion of implantation indications: from motor decoding to higher throughput. If MRI is framed as a capacity scale, it would transform imaging from a surgical tool into a screening tool, which is not under the same regulatory documents as existing medical devices.

In market mechanisms, the sellers are interface companies that need to portray the brain as measurable hardware, while the buyers are focused on implantation progress and the founder's worldview in the attention market. Event-driven discourse is rhetoric, not a new experimental endpoint. Funding still looks at electrode stability, infection rates, and bits per second, not the epistemology of this post. Beneficiaries are the implantation pipelines that tie pre-surgical imaging and surgical robots together; under pressure are public discussions that moralize or politicize intellectual differences, and misinterpret relevance as diagnosis.

Source: Public Information